TY - JOUR
T1 - Prediction of disability in schizophrenia
T2 - Symptoms, cognition, and self-assessment
AU - Harvey, Philip D.
AU - Strassnig, Martin T.
AU - Silberstein, Juliet
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: During the past year, Dr. Harvey has received consulting fees and travel reimbursements from Alkermes, Boehringer Ingelheim, Intra-Cellular Therapies, Jazz Pharma, Minerva Pharma, Otsuka America, Sanofi Pharma, Sunovion Pharma, Takeda Pharma, and Teva. He receives royalties from the Brief Assessment of Cognition in Schizophrenia. He is chief scientific officer of i-Function, Inc. He has a research grant from Takeda and from the Stanley Medical Research Foundation. These activities are unrelated to the content of this presentation.
Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: During the past year, Dr. Harvey has received consulting fees and travel reimbursements from Alkermes, Boehringer Ingelheim, Intra-Cellular Therapies, Jazz Pharma, Minerva Pharma, Otsuka America, Sanofi Pharma, Sunovion Pharma, Takeda Pharma, and Teva. He receives royalties from the Brief Assessment of Cognition in Schizophrenia. He is chief scientific officer of i-Function, Inc. He has a research grant from Takeda and from the Stanley Medical Research Foundation. These activities are unrelated to the content of this presentation.
PY - 2019/7
Y1 - 2019/7
N2 - Schizophrenia is associated with wide-ranging disability across multiple functional domains. There are several determinants of disability that have been identified to date, including cognitive and social cognitive impairments, impairments in everyday functional skills and social skills, difficulties in self-assessment of abilities, and negative symptoms. These impairments are related to different elements of disability, and disability and its predictors are not a single global dimension. Further, although psychotic symptoms have limited cross-sectional correlations with everyday functioning, emerging evidence suggests that long-term clinical stability, often induced through treatment with long-acting antipsychotic medications, is also associated with improvements in everyday functioning. This review addresses the characteristics and origins of disability, with treatment implications noted in each disability domains.
AB - Schizophrenia is associated with wide-ranging disability across multiple functional domains. There are several determinants of disability that have been identified to date, including cognitive and social cognitive impairments, impairments in everyday functional skills and social skills, difficulties in self-assessment of abilities, and negative symptoms. These impairments are related to different elements of disability, and disability and its predictors are not a single global dimension. Further, although psychotic symptoms have limited cross-sectional correlations with everyday functioning, emerging evidence suggests that long-term clinical stability, often induced through treatment with long-acting antipsychotic medications, is also associated with improvements in everyday functioning. This review addresses the characteristics and origins of disability, with treatment implications noted in each disability domains.
KW - cognition
KW - disability
KW - psychosis
KW - schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85078287686&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078287686&partnerID=8YFLogxK
U2 - 10.1177/2043808719865693
DO - 10.1177/2043808719865693
M3 - Review article
AN - SCOPUS:85078287686
VL - 10
JO - Journal of Experimental Psychopathology
JF - Journal of Experimental Psychopathology
SN - 2043-8087
IS - 3
ER -